Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SXTP
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
9 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-1.40
vs -0.39
Q3.23
N/A
-18.01
vs -0.26
Q4.23
N/A
-0.34
vs -0.35
Q1.24
N/A
-26.41
vs -0.47
Q2.24
N/A
-21.15
vs -1.40
Q3.24
N/A
-4.65
vs -18.01
Q4.24
N/A
-14.20
vs -0.34
Q1.25
N/A
-1.56
vs -26.41
Q2.25
N/A
-1.24
vs -21.15
Q3.25
N/A
-1.21
vs -4.65
Sales Growth
YoY
Current
Estimates
Q2.23
+32%
59.5K vs 45.2K
Q3.23
-70%
51.2K vs 168.2K
Q4.23
+156%
42.7K vs -75652
Q1.24
+751%
146.1K vs 17.2K
Q2.24
+111%
125.7K vs 59.5K
Q3.24
+164%
135.3K vs 51.2K
Q4.24
+441%
230.8K vs 42.7K
Q1.25
+12%
163.6K vs 146.1K
Q2.25
+155%
320K vs 125.7K
Q3.25
+181%
380K vs 135.3K
Return on Equity
QoQ
Q2.23
+15%
0.15
vs 0.14
Q3.23
+64%
0.64
vs 0.15
Q4.23
-41%
-0.41
vs 0.64
Q1.24
+6%
0.06
vs -0.41
Q2.24
-137%
-1.37
vs 0.06
Q3.24
-36%
-0.36
vs -1.37
Q4.24
-51%
-0.51
vs -0.36
Q1.25
-46%
-0.46
vs -0.51
Institutionnal Ownership
Quote Panel
Key Metrics
Forecast
1257%2026-Revenue
-244%2026-EPS
6%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
SXTP
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.05 ( 3.91%)
Pre-market 1.33$-0.01 (-0.38%)
Relative Strenght
2
Volume Buzz
-62%
Earning Acce
No
Dist 52w H.
90%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SXTP compares to sector?
SXTP
0x